Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | AR | P10275 | 1/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 10/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.53 |
| ▸ | PGR | P06401 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.49 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3476071 | 1.00 | LMNA (0.61) | LMNAMAPTARCYP19A1CYP3A4 | |
| SCHEMBL4218580 | 0.92 | LMNA (0.59) | LMNAMAPTARCYP19A1CYP3A4 | |
| SCHEMBL4210068 | 0.90 | LMNA (0.59) | LMNAMAPTARCYP19A1CYP3A4 | |
| SCHEMBL3476075 | 0.90 | LMNA (0.59) | LMNAMAPTARCYP19A1CYP3A4 | |
| SCHEMBL11822457 | 0.90 | LMNA (0.58) | LMNAMAPTARCYP19A1CYP3A4 | |
| SCHEMBL4220494 | 0.89 | LMNA (0.57) | LMNAMAPTARCYP19A1CYP3A4 | |
| SCHEMBL11583875 | 0.89 | LMNA (0.68) | LMNAMAPTARCYP19A1CYP3A4 | |
| SCHEMBL28364035 | 0.87 | LMNA (0.64) | LMNAMAPTCYP19A1CYP3A4NR3C1 | |
| SCHEMBL11230269 | 0.86 | NR3C1 (0.71) | LMNAARCYP3A4NR3C1PGR | |
| SCHEMBL11806510 | 0.83 | LMNA (0.57) | LMNAMAPTARCYP19A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785425-B2 | 11β-hydroxyandrosta-4-ene-3-ones | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. | 2014-07-22 | — | — | US | disclosed |
| US-20090054388-A1 | NOVEL 11 BETA-HYDROXYANDROSTA-4-ENE-3-ONES | SUN PHARMA ADVANCE RESEARCH COMPANY (IN) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054388-A1 | NOVEL 11 BETA-HYDROXYANDROSTA-4-ENE-3-ONES | HSD11B1, HSD3B1, HSD3B2 | LMNA 1076/4885MAPT 4793/4885AR 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.